Validation of updated ELN 2022 risk stratification in adult patients with AML
Ruhnke et al. published a retrospective cohort study in Blood Advances validating the prognostic value of the 2022 ELN classification in patients with newly diagnosed AML.
Related Articles
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.
ICIs Result in Increased Rates of High-Grade irAEs for Older Patients With Breast Cancer
The risk of developing high-grade immune-related AEs was heightened among patients with breast cancer who were older and who had chronic kidney disease.
FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative…
Olaparib, Bevacizumab Combination Safe in Older Patients With Ovarian Cancer – Oncology Nurse Advisor
Adding olaparib to bevacizumab was safe with good quality of life in older patients with advanced ovarian cancer.
Patients With Advanced Breast Cancer May Have Higher Risk of Cardiovascular Disease
Researchers found an association between cardiovascular disease and more advanced stage of breast cancer at diagnosis, “independent of factors associated with delayed diagnosis and shared…
Effective and Well-Tolerated Combo in ER+/HER2– Metastatic Breast Cancer
Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether…
JAB-8263 Monotherapy Demonstrates Early Promise in Myelofibrosis
JAB-8263 given at once-daily doses ranging from 0.125 mg to 0.3 mg proved to be well tolerated in patients with myelofibrosis.
Plasma cell and cancer stem cell crosstalk in glioblastoma
Plasma cells (PCs) are the main producers of antibodies and have context-dependent roles in tumor immunity. In this issue of Cancer Cell, Gao et al. report…
